Valbiotis gains nearly 18% in Paris, as Invest Securities confirms this morning its buy rating on the stock, with a target price raised from 10.3 to 12.3 euros

Valbiotis is buoyed by last night's announcement of the "broad success" of a Phase II/III clinical trial for a diabetes treatment. This 3-year "clinical adventure" achieved its primary endpoint of reducing fasting glycemia "with high statistical significance", as Invest points out.

Despite the absence of exhaustive data (the full report on all the data is expected this summer), the success of the study is very positive and will trigger a milestone payment of 4 million Swiss francs from Nestlé Health Science (NHS) as part of the strategic global partnership.

"This clinical success significantly strengthens the Group's credibility and validates the strategy", underlines Invest Securities.

Copyright (c) 2023 CercleFinance.com. All rights reserved.